Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Joint by Joint

Gretchen Henkel  |  Issue: November 2006  |  November 1, 2006

Dr. Strand’s close affiliation with Dr. Sharp began in the mid-1990s, when she “pulled him out of retirement” to consult on the leflunomide program with the FDA—“for which his wife has never forgiven me!” she laughs.

Dr. Sharp came to the FDA “at least twice,” she remembers, to help teach assessment of radiographic damage and change. “I don’t think anyone else could have gone to the FDA and shown them how to read these films other than John, with his very unassuming manner.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“He’s been a wonderful man to work with,” says Dr. Strand. “He really has not only this panache, but clout. And he’s so modest.”

At one point, recalls Dr. Strand, Dr. Sharp tried to “un-name” the Sharp score. While co-writing with her a review paper published in Arthritis & Rheumatism, Dr. Sharp sent back a draft stating the score should simply be referred to as “a composite score” rather than the Total Sharp Score [or its modifications].4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Slowing Down—of a Sort

Now in his 80s, Dr. Sharp admits to a little slowing down, but one could hardly call his current activity level retired. Among other projects, Dr. Sharp has been an active co-chair of an OMERACT group that is working on developing computer-based methods of joint space measurement. “We were both deeply involved in the workshop on repair, and also in preparation of all the scoring for big projects,” says Dr. van der Heijde. “It’s still a pleasure to read [X-rays] with him and to hear his opinions.”

In addition to his work with OMERACT committees, Dr. Sharp continues to attend ACR meetings and has lively communications with researchers around the world. His time while at home in Bainbridge is also full: He and his wife walk, garden, read, and frequently spend time with a nearby son and grandchildren. Dr. Sharp also volunteers with a local Rotary Club and finds time for woodworking.

Asked to characterize his contributions to the field of rheumatology, Dr. Sharp appears reticent to paint his importance too broadly. He compares the method with a once-common attraction at country fairs, where you pay a fee to have someone guess your weight. Even if you win, the prize is worth less than the fee you already paid.

“The point I’m trying to make is that people get pretty good at making estimates like that,” says Dr. Sharp. “Those of us who’ve spent some time looking at X-rays get pretty good at estimating how bad the damage in a particular joint is. One thing that makes it much easier, in trials and in clinical practice, is comparing two or three films over time, looking for change.”

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Practice SupportProfilesResearch Rheum Tagged with:Clinical researchMetricsOutcome measuresRheumatoid Arthritis (RA)

Related Articles

    Remembrance of John Sharp, MD, Rheumatologist Extraordinaire

    December 1, 2008

    Dr. Sharp was a rheumatology pioneer who left a lasting mark on the field

    In the Lungs: Asthma & COPD May Be Early, Independent Risk Factors for RA

    June 1, 2020

    Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…

    The Great Debate: Should Jakinibs Be Used Before Biologics after Methotrexate Failure in RA?

    November 9, 2020

    ACR CONVERGENCE 2020—In many ways, the current plethora of treatment options for rheumatoid arthritis patients represents an embarrassment of riches. However, while many therapeutics approved by the U.S. Food & Drug Administration (FDA) are available, knowing the order in which to try these medications with patients can be quite challenging. In The Great Debate, held…

    Rheumatology’s Divergent Thinkers

    February 1, 2008

    OMERACT selects outcomes measures with an egalitarian process

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences